1 Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians (2021).
2 Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA: a cancer journal for clinicians 69, 7-34 (2019).
3 Lam, J. S., Shvarts, O., Leppert, J. T., Figlin, R. A. & Belldegrun, A. S. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. The Journal of urology 173, 1853-1862 (2005).
4 Tannir, N. M. et al. (American Society of Clinical Oncology, 2019).
5 Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine 380, 1116-1127 (2019).
6 Motzer, R. J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. Journal of clinical oncology 17, 2530-2530 (1999).
7 Heng, D. Y. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large, multicenter study. Journal of clinical oncology 27, 5794-5799 (2009).
8 Hu, B. et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clinical Cancer Research 20, 6212-6222 (2014).
9 Zhong, J.-H., Huang, D.-H. & Chen, Z.-Y. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget 8, 75381 (2017).
10 Chen, J.-H. et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World journal of gastroenterology 23, 6261 (2017).
11 Tong, Y.-S., Tan, J., Zhou, X.-L., Song, Y.-Q. & Song, Y.-J. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. Journal of translational medicine 15, 1-10 (2017).
12 Lolli, C. et al. Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone. Frontiers in pharmacology 7, 376 (2016).
13 Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. JNCI: Journal of the National Cancer Institute 106 (2014).
14 Rossi, L. et al. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Annals of surgical oncology 22, 1377-1384 (2015).
15 Templeton, A. J. et al. Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy. European urology 70, 358-364 (2016).
16 Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. nature 454, 436-444 (2008).
17 Schumacher, D., Strilic, B., Sivaraj, K. K., Wettschureck, N. & Offermanns, S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer cell 24, 130-137 (2013).
18 Nunno, V. D. et al. Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. Immunotherapy 11, 631-643 (2019).
19 Teishima, J. et al. Impact of neutrophil-to-lymphocyte ratio on effects of targeted therapy for metastatic renal cell carcinoma patients with extrapulmonary metastasis. Canadian Urological Association Journal 11, E207 (2017).
20 Huszno, J., Kolosza, Z., Mrochem-Kwarciak, J., Rutkowski, T. & Skladowski, K. The role of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and platelets in the prognosis of metastatic renal cell carcinoma. Oncology 97, 7-17 (2019).
21 Tanaka, N. et al. in Urologic Oncology: Seminars and Original Investigations. 39. e19-39. e28 (Elsevier).
22 Diem, S. et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung cancer 111, 176-181 (2017).
23 An, X. et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 15, 516-522 (2010).
24 Walsh, S., Cook, E., Goulder, F., Justin, T. & Keeling, N. Neutrophil‐lymphocyte ratio as a prognostic factor in colorectal cancer. Journal of surgical oncology 91, 181-184 (2005).
25 Lolli, C. et al. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget 7, 54564 (2016).
26 Chrom, P., Zolnierek, J., Bodnar, L., Stec, R. & Szczylik, C. External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model. International journal of clinical oncology 24, 526-532 (2019).
27 Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356, 115-124, doi:10.1056/NEJMoa065044 (2007).